We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Imaxio Sells Genomics Division to Hybrigenics


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Imaxio Sells Genomics Division to Hybrigenics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The work is based on proprietary IMX313 antigen re-engineering technology, which aims to create a significant improvement in the immunogenicity and therefore the effectiveness of each vaccine in which it is used.

“There is a major need to improve the efficacy of vaccine candidates in human and animal health. We will rise to this challenge by focusing on the development of our IMX313 technology,” said Alexandre le Vert, chief executive officer of Imaxio. “IMX313 may resolve the problems of developing vaccines and immunotherapies for key therapeutic indications such as tuberculosis, staphylococcal infection, influenza and malaria.”

Imaxio recently initiated a Phase I clinical trial of IMX313 in tuberculosis and is one of the coordinators of the EU-funded Bellerophon project to develop a vaccine against Staphylococcus aureus.

In France Imaxio already markets Spirolept(R), a human vaccine indicated for preventing a work-related infectious disease, and Trolovol(R), an orphan drug indicated for a congenital metabolic disease. These core biopharmaceutical products generated revenue of EUR 2.1 million in 2012, providing significant financial support for the continuation of R&D activity.

The financial terms of the agreement were not disclosed.

Advertisement